Printed From BioPortfolio.com
FDA approves alectinib as first-line treatment for ALK positive NSCLC
10:32 EST 7 Nov 2017 | ecancermedicalscience
The U.S. Food and Drug Administration has granted regular approval to alectinib (ALECENSA, Hoffmann-La Roche, Inc./Genentech, Inc.) for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as...
Original Article: FDA approves alectinib as first-line treatment for ALK positive NSCLC
